Biotech Values

[jq1234]

VLST-007 (hCD47-hFc): It would be interesting to see where this one turns up.

VLST’s most advanced drug candidate was VLST-007 (hCD47-hFc), a dimeric protein comprised of human CD47 extracellular domain fused to the Fc portion of a human IgG1 molecule that is designed to modulate the activity of CD47 and its extracellular ligand, signal regulatory protein A (SIRPa). CD47-Fc binding to SIRPa inhibits the activation of myeloid cells, which are important mediators of inflammation in autoimmune diseases. VLST-007 is being developed as an inhibitor of inflammation for use in autoimmune and inflammatory conditions and has completed preclinical development. VLST is actively seeking a partner for the continued development of the programme.

http://ojs.pharmadeals.net:5555/index.php/pdr/article/view/cr1807/html

VLST-007 (hCD47-hFc) was sold to unnamed buyer last month:

The names of the buyers, and the price they paid for VLST’s components, aren’t being disclosed... One buyer has scooped up an antibody drug candidate for cancer that’s being prepped for mid-stage clinical trials [I assume CD40 program licensed from PFE]. Another buyer has obtained VLST’s proprietary drug discovery engine, preclinical drug candidates, and related intellectual property.

http://www.xconomy.com/seattle/2013/08/07/vlst-after-nine-years-and-50m-sheds-assets-and-winds-down/